Clinically, E2F1 displays a remarkable potential value for ESCC prognosis, which has improved our understanding of the molecular pathology of E2F1, thus providing a possible therapeutic target for ESCC treatment. The gene discussed is E2F1; the disease is esophageal squamous cell carcinoma.